CCG1423 is an inhibitor of Rho signaling that inhibits serum response factor (SRF); it displays anti-metastatic, anti-diabetic, and anti-fibrotic activities. CCG1423 binds myocardin-related transcription factor A (MRTF-A), preventing its accumulation and potentially inhibiting the epithelial-to-mesenchymal transition (EMT). CCG1423 also inhibits invasiveness of prostate cancer cells. In animal models of diabetes pathogenesis, this compound improves glucose uptake and tolerance.
| Cas No. | 285986-88-1 |
|---|---|
| Purity | ≥98% |
| Formula | C18H13ClF6N2O3 |
| Formula Wt. | 454.75 |
| IUPAC Name | N-({1-[(4-Chlorophenyl)amino]-1-oxo-2-propanyl}oxy)-3,5-bis(trifluoromethyl)benzamide |
| Solubility | DMSO: 90 mg/mL |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Hayashi K, Watanabe B, Nakagawa Y, et al. RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling. PLoS One. 2014 Feb 18;9(2):e89016. PMID: 24558465.
Bell JL, Haak AJ, Wade SM, et al. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3826-32. PMID: 23707258.
Jin W, Goldfine AB, Boes T, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar;121(3):918-29. PMID: 21393865.
